Search tips
Search criteria 


Logo of arthresbiomed central web sitesearch.manuscript submission.see also journal with issn 1478-6354registration.reference to the article.journal front page.
Arthritis Res. 2001; 3(Suppl A): P100.
Published online 2001 January 26. doi:  10.1186/ar269
PMCID: PMC3273270

New antirheumatic effects of biphosphonate treatment

Recently, secondary osteoporosis therapy has been as new strategy for combination treatment rheumatic disease. We have stadied the efficacy of pamidronate treatment in the contexst of combination therapy rheumatic disease.

The complex chek up of 27 patients with rheumatic disease: (rheumatoid arthritis (RA) - 15, systemic lupus erythematosus (SLE) - 3, ankylosing spondilitis (AS) - 2, Reiter syndrome (RS) - 2, sistemic sclerosis (SS) - 1), average age 46,2 year.

In all of them the decrease of bone mineral density were revealed. Patients had standart non-change cytotoxic therapy, were treated with <<Aredia>> (pamidronate, Novartis pharma, 30 mg i.v. infusion). The control clinical and laboratory examination were carry out after 3 and 6 month. In 24 (88,9%) patients significant improvement was observed: decrease the tender-joint count and swollen-joint count of 25 percent; erythrocyte sedimentation rate decreased by 11,5 mm per hour; serum level of antiphospholipide antibodies decreased (P < 0,05), Ig G serum levels and of cyrculating erithroid precursors decreased (P < 0,05); CD 3+, CD 4+, CD 8+, CD 20+ levels were normalysed. The regulary pamidronate infusion may benefit from optimisation of the antirheumatic therapy for patients with secondary osteoporosis.

Articles from Arthritis Research are provided here courtesy of BioMed Central